Search

Your search keyword '"Koomen, John"' showing total 1,092 results

Search Constraints

Start Over You searched for: Author "Koomen, John" Remove constraint Author: "Koomen, John"
1,092 results on '"Koomen, John"'

Search Results

203. Integrated proteomics-based physical and functional mapping of AXL kinase signaling pathways and inhibitors define its role in cell migration

205. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

206. Abstract P018: Integrative proteomics of PARP1 protein complexes and post-translational modifications implicates DDR and AKT-mTOR signaling in mediating response or primary resistance of ovarian carcinoma cells to PARP1 inhibitors

209. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

211. Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies

212. Proteomic Contributions to Personalized Cancer Care

214. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer

217. Targeted mass-spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP kinase, and AKT signaling

218. Abstract 1635: Sirt2 blockade promotes T cell metabolism and restores the anti-tumor immunity

219. Fucosylated Proteome Profiling Identifies a Fucosylated, Non-Ribosomal, Stress-Responsive Species of Ribosomal Protein S3

220. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma

221. A Mutational Survey of Acral Nevi

222. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determine myeloma CAR-T outcomes

223. Unveiling the Molecular Features of SCLC With a Clinical RNA Expression Panel

224. Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling.

227. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer

228. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma

229. Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition

230. Anion template effect on the self-assembly and interconversion of metallacyclophanes

231. Binding of DNA purine sites to dirhodium compounds probed by mass spectrometry

232. Lipid/peptide/nucleotide separation with MALDI-ion mobility-TOF MS

236. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response

237. 280 Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients

238. 93 Targeting sirt2 rescues the metabolic fitness and effector functions of tumor-reactive T cells within the metabolically restricted tumor microenvironment

240. Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment

244. Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells

245. Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial

246. Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes

247. TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes

248. CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.

249. Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance

Catalog

Books, media, physical & digital resources